The anti-COVID drug developed by the Vancouver company gains approval for emergency use in Canada

The content of the article continued

AbCellera is entitled to receive a specific percentage of the proceeds Lilly receives from these sales.

“As a Canadian company, we are proud to contribute to the global fight against COVID-19 and we hope that our efforts will help people in Canada and around the world in the face of this medical emergency,” said Hansen, a former professor of the ‘UBC which owns 26 percent of the private company.

According to Bloomberg News, AbCellera is expected to be worth several billion dollars after going public.

Eli Lilly struck a deal with AbCellera last March to co-develop antibody drugs for the treatment and prevention of COVID-19, using Abcellera’s technology that quickly identifies immune cells that can be replicated and used to attack infections.

AbCellera researchers used a blood sample from one of the first COVID-19 survivors in the United States to start their work.

The company’s antibody discovery platform provides “lab-on-a-chip” technology to help biopharmaceutical companies identify next-generation drug candidates.

The Eli Lilly / AbCellera company reported a reduction in viral load and symptom and hospitalization rates in a study of 800 patients.

[email protected]